Profile data is unavailable for this security.
About the company
Prestige Consumer Healthcare Inc. is consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club and e-commerce stores in North America (the United States and Canada) and in Australia and certain other international markets. It operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
- Revenue in USD (TTM)1.11bn
- Net income in USD205.95m
- Incorporated2004
- Employees570.00
- LocationPrestige Consumer Healthcare Inc660 White Plains Rd.TARRYTOWN 10591United StatesUSA
- Phone+1 (914) 524-6800
- Fax+1 (302) 655-5049
- Websitehttps://www.prestigebrands.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Twist Bioscience Corp | 312.97m | -208.73m | 2.44bn | 923.00 | -- | 5.12 | -- | 7.80 | -3.60 | -3.60 | 5.39 | 8.03 | 0.4501 | 6.40 | 7.93 | 339,083.40 | -30.02 | -28.50 | -33.49 | -31.56 | 42.61 | 39.40 | -66.69 | -93.82 | 4.54 | -- | 0.00 | -- | 27.69 | 41.91 | -2.01 | -- | -19.22 | -- |
| Catalyst Pharmaceuticals Inc | 460.48m | 142.80m | 2.52bn | 167.00 | 18.04 | 3.82 | 13.99 | 5.48 | 1.17 | 1.17 | 3.78 | 5.54 | 0.777 | 4.34 | 8.66 | 2,757,377.00 | 24.10 | 25.42 | 27.94 | 29.81 | 86.32 | 85.63 | 31.01 | 30.87 | 4.92 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Amneal Pharmaceuticals Inc | 2.68bn | -184.45m | 2.60bn | 7.70k | -- | -- | 32.33 | 0.9712 | -0.6835 | -0.6835 | 9.08 | -0.3016 | 0.75 | 2.96 | 3.73 | 348,106.50 | -4.10 | -4.80 | -5.45 | -5.93 | 35.34 | 34.76 | -5.46 | -9.00 | 0.8372 | 1.26 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Vericel Corp | 226.84m | 3.55m | 2.83bn | 314.00 | 740.18 | 10.96 | 317.66 | 12.46 | 0.0774 | 0.0774 | 4.69 | 5.23 | 0.6403 | 4.56 | 5.14 | 722,433.10 | 1.00 | -3.07 | 1.12 | -3.50 | 71.47 | 67.87 | 1.56 | -4.49 | 4.23 | -- | 0.0009 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| PTC Therapeutics, Inc. | 900.66m | -453.20m | 3.24bn | 988.00 | -- | -- | -- | 3.59 | -5.94 | -5.94 | 11.79 | -13.70 | 0.5807 | 1.97 | 4.93 | 911,603.30 | -29.22 | -26.71 | -45.34 | -33.46 | 92.20 | 93.94 | -50.32 | -83.80 | 2.04 | -0.7925 | 1.79 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Apellis Pharmaceuticals Inc | 715.22m | -250.10m | 3.42bn | 702.00 | -- | 14.15 | -- | 4.78 | -2.04 | -2.04 | 5.81 | 1.94 | 0.8316 | 0.8814 | 3.19 | 1,018,828.00 | -29.08 | -73.88 | -37.24 | -90.03 | 86.47 | -- | -34.97 | -326.49 | 3.73 | -9.20 | 0.656 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Perrigo Company PLC | 4.39bn | -146.90m | 3.70bn | 9.14k | -- | 0.8117 | 20.07 | 0.8434 | -1.07 | -1.17 | 32.07 | 33.45 | 0.40 | 2.46 | 5.58 | 480,525.20 | -1.34 | -0.1148 | -1.51 | -0.1315 | 36.07 | 35.28 | -3.34 | -0.2985 | 1.77 | 1.26 | 0.51 | -- | 4.58 | -0.3238 | 96.64 | -- | -5.95 | 7.52 |
| Organon & Co | 6.41bn | 1.30bn | 3.79bn | 10.00k | 2.92 | 7.69 | 2.43 | 0.5919 | 5.04 | 5.04 | 24.81 | 1.91 | 0.5394 | 2.08 | 3.85 | 640,900.00 | 10.95 | 16.53 | 14.08 | 20.97 | 58.26 | 65.12 | 20.30 | 26.79 | 1.21 | 2.73 | 0.9467 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.91 | -- |
| Prestige Consumer Healthcare Inc | 1.11bn | 205.95m | 4.08bn | 570.00 | 20.14 | 2.36 | 17.20 | 3.68 | 4.11 | 4.11 | 22.14 | 35.03 | 0.334 | 3.13 | 6.90 | 1,948,525.00 | 6.19 | 3.69 | 6.42 | 3.84 | 55.21 | 56.79 | 18.54 | 12.19 | 2.10 | 5.68 | 0.3779 | 0.00 | -0.21 | 2.89 | 354.34 | -- | -1.84 | -- |
| BridgeBio Pharma Inc | 217.77m | -438.86m | 4.33bn | 550.00 | -- | -- | -- | 19.89 | -2.41 | -2.41 | 1.19 | -6.51 | 0.33 | -- | -- | 395,936.40 | -67.62 | -72.44 | -85.06 | -89.72 | 98.90 | 94.41 | -204.94 | -1,225.66 | -- | -9.40 | 3.43 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Axsome Therapeutics Inc | 338.46m | -310.96m | 4.54bn | 545.00 | -- | 49.32 | -- | 13.42 | -6.54 | -6.54 | 7.11 | 1.92 | 0.5824 | 2.49 | 3.34 | 621,022.00 | -53.51 | -64.55 | -73.04 | -82.23 | 91.09 | -- | -91.87 | -227.05 | 2.37 | -60.51 | 0.6648 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| ADMA Biologics Inc | 382.81m | 68.13m | 5.05bn | 624.00 | 77.34 | 21.78 | 66.17 | 13.20 | 0.2763 | 0.2763 | 1.61 | 0.981 | 1.04 | 1.17 | 9.40 | 613,475.40 | 18.42 | -24.80 | 20.87 | -28.00 | 48.93 | 17.40 | 17.80 | -51.31 | 3.26 | 7.58 | 0.3041 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Avidity Biosciences Inc | 10.12m | -280.49m | 5.21bn | 253.00 | -- | 3.45 | -- | 514.76 | -2.90 | -2.90 | 0.1028 | 12.64 | 0.0091 | -- | -- | 39,988.14 | -25.34 | -31.61 | -27.05 | -34.45 | -- | -- | -2,772.45 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
Data as of Nov 22 2024. Currency figures normalised to Prestige Consumer Healthcare Inc's reporting currency: US Dollar USD
58.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 7.35m | 14.84% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.59m | 11.29% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 2.85m | 5.76% |
| Ariel Investments LLCas of 30 Sep 2024 | 2.78m | 5.62% |
| Macquarie Investment Management Business Trustas of 30 Sep 2024 | 2.67m | 5.40% |
| Victory Capital Management, Inc. (Investment Management)as of 30 Sep 2024 | 2.07m | 4.17% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.01m | 4.05% |
| Allspring Global Investments LLCas of 30 Sep 2024 | 1.54m | 3.10% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.33m | 2.68% |
| Congress Asset Management Co. LLPas of 30 Sep 2024 | 865.12k | 1.75% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
